Ligand Pharmaceuticals Q1 Earnings Call Highlights Ligand Pharmaceuticals (
NASDAQ:LGND ) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.
CEO Todd Davis tol
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing Euronet Worldwide encompasses ATM and electronic funds transfer (EFT) services, prepaid distribution, and money transfer, resulting in a more complex structure than that of a typical payments network. The central consideration for investors is whether growth across these networks can translate into sustained profitability.
Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million Specializing in offshore marine support, Tidewater serves global energy clients across oil, gas, and windfarm projects.
CLO Sells LGND 5,000 Shares for $1.0 Million Ligand Pharmaceuticals, a leader in drug licensing and royalties, reported a notable insider sale amid strong recent share performance.
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.
Rice Hall James Buys QuidelOrtho Stock QuidelOrtho develops diagnostic technologies for healthcare providers worldwide, spanning labs, clinics, and retail settings.
Rice Hall James Buys Stride Stock Stride delivers online and blended education solutions for K-12, career, and adult learners through proprietary technology platforms.
The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026 The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years of dominance by a handful of "Magnificent 7" companies, the tide has turned toward the "median stock,
This $38.8 Million Vicor Bet Is Getting Bigger Amid a 200% Stock Surge Vicor Corporation designs advanced power conversion solutions for sectors like aerospace, defense, and industrial automation.
Sportradar Stock Down 26%, but One Fund Just Disclosed a New $12.6 Million Stake Specializing in sports data and analytics, Sportradar serves betting operators, leagues, and media with real-time technology solutions.
What Investors Should Know as One Fund Sells $11 Million of Cavco Industries Stock This Arizona-based firm provides factory-built homes and modular units to residential and commercial clients across North America.
Fund Sells $23 Million in Globalstar as Stock Surges 170% in One Year Globalstar delivers satellite communications and IoT connectivity to enterprise and government clients across critical industries worldwide.
Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out This digital banking platform targets U.S. mass market consumers with mobile-first, fee-free services and strategic bank partnerships.
Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth Solaris Energy Infrastructure delivers automation and logistics solutions to U.S. oil and gas operators using proprietary technologies.
Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base.
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move.
Why One Small-Cap Fund Bought $11 Million in Cellebrite Stock Last Quarter A specialist small-cap fund just doubled down on a digital-intelligence company that's underperforming the broader market.
This Fund Cut $7.3 Million of Atlas Energy Stock as the Company Suspends Its Dividend to Help Fuel Growth One fund just took a step back from a struggling energy name—right as the company suspended its dividend to fund future growth.
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.
